SiRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/- with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors

Oncogene

Volumn 32, Issue 48, 2013, Pages 5458-5470

  Bohringer M ^a   Obermeier, K ^a   Griner, N ^b   Waldraff, D ^a   Dickinson, E ^b   Eirich, K ^c   Schindler, D ^c   Hagen, M ^b   Jerry, D J ^b   Wiesmuller L ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Crosslink repair; Fanconi anemia; Li Fraumeni mouse model; Modifier of breast cancer susceptibility; P53

Indexed keywords

BRCA2 PROTEIN; FANCONI ANEMIA GROUP CD1 PROTEIN; FANCONI ANEMIA GROUP CJ PROTEIN; FANCONI ANEMIA GROUP CO PROTEIN; FANCONI ANEMIA PROTEIN; PROTEIN P53; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CANCER SUSCEPTIBILITY; CHROMOSOME BREAKAGE; CONTROLLED STUDY; CROSS LINKING; DNA END JOINING REPAIR; DOUBLE STRANDED DNA BREAK; FAMILIAL CANCER; FEMALE; FLUORESCENCE; G2 PHASE CELL CYCLE CHECKPOINT; GENE REPLICATION; GENETIC SCREENING; HETEROZYGOSITY; HOMOLOGOUS RECOMBINATION; MOUSE; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DISEASE RESISTANCE; DNA BREAKS, DOUBLE-STRANDED; DNA REPAIR; FANCONI ANEMIA; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED BALB C; MICE, INBRED C57BL; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SPECIES SPECIFICITY; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84889087618     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.38     Document Type: Article

References (56)

1. Tainsky MA, Bischoff FZ, Strong LC. Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells. Cancer Metastasis Rev 1995; 14: 43-48
2. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci USA 2008; 105: 11264-11269
3. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L et al. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 2005; 65: 5561-5570
4. Shao C, Deng L, Henegariu O, Liang L, Stambrook PJ, Tischfield JA. Chromosome instability contributes to loss of heterozygosity in mice lacking p53. Proc Natl Acad Sci USA 2000; 97: 7405-7410
5. Lu X, Lozano G, Donehower LA. Activities of wildtype and mutant p53 in suppression of homologous recombination as measured by a retroviral vector system. Mutat Res 2003; 522: 69-83
6. Bertrand P, Saintigny Y, Lopez BS. p530s double life: Transactivation-independent repression of homologous recombination. Trends Genet 2004; 20: 235-243
7. Gatz SA, Wiesmu? ller L. p53 in recombination and repair. Cell Death Differ 2006; 13: 1003-1006
8. Chompret A, Brugieres L, Ronsin M, Gardes M, Dessarps-Freichey F, Abel A et al. p53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br J Cancer 2000; 82: 1932-1937
9. Kuperwasser C, Hurlbut GD, Kittrell FS, Dickinson ES, Laucirica R, Medina D et al. Development of spontaneous mammary tumors in BALB/c p53 heterozygous mice. A model for Li-Fraumeni syndrome. Am J Pathol 2000; 157: 2151-2159
10. Blackburn AC, Brown JS, Naber SP, Otis CN, Wood JT, Jerry DJ. BALB/c alleles for prkdc and cdkn2a interact to modify tumor susceptibility in trp53/- mice. Cancer Res 2003; 63: 2364-2368
11. Blackburn AC, McLary SC, Naeem R, Luszcz J, Stockton DW, Donehower LA et al. Loss of heterozygosity occurs via mitotic recombination in Trp53 mice and associates with mammary tumor susceptibility of the BALB/c strain. Cancer Res 2004; 64: 5140-5147
12. Blackburn AC, Hill LZ, Roberts AL, Wang J, Aud D, Jung J et al. Genetic mapping in mice identifies DMBT1 as a candidate modifier of mammary tumors and breast cancer risk. Am J Pathol 2007; 170: 2030-2041
13. Koch JG, Gu X, Han Y, El-Naggar AK, Olson MV, Medina D et al. Mammary tumor modifiers in BALB/cJ mice heterozygous for p53. Mamm Genome 2007; 18: 300-309
14. Szpirer C, Szpirer J. Mammary cancer susceptibility: Human genes and rodent models. Mamm Genome 2007; 18: 817-831
15. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D et al. COSMIC: Mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 2011; 39(Database issue): D945-D950
16. Keimling M, Deniz M, Varga D, Stahl A, Schrezenmeier H, Kreienberg R et al. The power of DNA double-strand break (DSB) repair testing to predict breast cancer susceptibility. FASEB J 2012; 26: 2094-2104
17. Okayasu R, Suetomi K, Yu Y, Silver A, Bedford JS, Cox R et al. A deficiency in DNA repair and DNA-PKcs expression in the radiosensitive BALB/c mouse. Cancer Res 2000; 60: 4342-4345
18. Mitchell J, Smith GCM, Curtin NJ. Poly(ADP-Ribose) polymerase-1 and dnadependent protein kinase have equivalent roles in double strand break repair following ionizing radiation. Int J Radiat Oncol Biol Phys 2009; 75: 1520-1527
19. Asaad NA, Zeng ZC, Guan J, Thacker J, Iliakis G. Homologous recombination as a potential target for caffeine radiosensitization in mammalian cells: Reduced caffeine radiosensitization in XRCC2 and XRCC3 mutants. Oncogene 2000; 19: 5788-5800
20. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights. Mutat Res 2009; 668: 54-72
21. Ho TV, Scha?rer OD, Translesion DNA. Synthesis polymerases in DNA crosslink repair. Environ Mol Mutagen 2010; 51: 552-566
22. Schild D, Wiese C. Overexpression of RAD51 suppresses recombination defects: A possible mechanism to reverse genomic instability. Nucleic Acids Res 2010; 38: 1061-1070
23. Heacock ML, Stefanick DF, Horton JK, Wilson SH. Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks. DNA Repair 2010; 9: 929-936
24. Gagou ME, Zuazua-Villar P, Meuth M. Enhanced H2AX phosphorylation, DNA replication fork arrest, and cell death in the absence of Chk1. Mol Biol Cell 2010; 21: 739-752
25. Auerbach AD, Rogatko A, Schroeder-Kurth TM. International Fanconi Anemia Registry: Relation of clinical symptoms to diepoxybutane sensitivity. Blood 1989; 73: 391-396
26. Vaz F, Hanenberg H, Schuster B, Barker K, Wiek C, Erven V et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet 2010; 42: 406-411
27. Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 2007; 39: 159-161
28. Kavitha CV, Choudharty B, Raghavan SC, Muniyappa K. Differential regulation of MRN (Mre11-Rad50-Nbs1) complex subunits and telomerase activity in cancer cells. Biochem Biophys Res Commun 2010; 399: 575-580
29. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer Cell 2007; 11: 103-105
30. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410-414
31. Akyu? z N, Boehden GS, Su? sse S, Rimek A, Preuss U, Scheidtmann KH et al. DNA substrate dependence of p53-mediated regulation of double-strand break repair. Mol Cell Biol 2002; 22: 6306-6317
32. Marmorstein LY, Kinev AV, Chan GK, Bochar DA, Beniya H, Epstein JA et al. A human BRCA2 complex containing a structural DNA binding component influences cell cycle progression. Cell 2001; 104: 247-257
33. Hamimes S, Arakawa H, Stasiak AZ, Kierzek AM, Hirano S, Yang YG et al. RDM1, a novel RNA recognition motif (RRM)-containing protein involved in the cell response to cisplatin in vertebrates. J Biol Chem 2005; 280: 9225-9235
34. Lin WY, Camp NJ, Cannon-Albright LA, Allen-Brady K, Balasubramanian S, Reed MW et al. A role for XRCC2 gene polymorphisms in breast cancer risk and survival. J Med Genet 2011; 48: 477-484
35. He XF, Wei W, Su J, Yang ZX, Liu Y, Zhang Y et al. Association between the XRCC3 polymorphisms and breast cancer risk: Meta-analysis based on case-control studies. Mol Biol Rep 2012; 39: 5125-5134
36. Shamseldin HE, Elfaki M, Alkuraya FS. Exome sequencing reveals a novel Fanconi group defined by XRCC2 mutation. J Med Genet 2012; 49: 184-186
37. Ludwig T, Chapman DL, Papaioannou VE, Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997; 11: 1226-1241
38. Bahassi EM, Ovesen JL, Riesenberg AL, Bernstein WZ, Hasty PE, Stambrook PJ. The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 2008; 27: 3977-3985
39. Sy SM, Huen MS, Chen J. MRG15 is a novel PALB2-interacting factor involved in homologous recombination. J Biol Chem 2009; 284: 21127-21131
40. Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J et al. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J Cell Sci 2010; 123: 1124-11230
41. Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 2011; 145: 529-542
42. Villani G, Hubscher U, Gironis N, Parkkinen S, Pospiech H, Shevelev I et al. In vitro gap-directed translesion DNA synthesis of an abasic site involving human DNA polymerases epsilon, lambda, and beta. J Biol Chem 2011; 286: 32094-32104
43. Go? hler T, Munoz IM, Rouse J, Blow JJ. PTIP/swift is required for efficient PCNA ubiquitination in response to DNA damage. DNA Repair 2008; 7: 775-787
44. Shevelev IV, Ramadan K, Hu?bscher U. The TREX2 30 -450 exonuclease physically interacts with DNA polymerase delta and increases its accuracy. ScientificWorld Journal 2002; 2: 275-281
45. Maloisel L, Fabre F, Gangloff S. DNA polymerase delta is preferentially recruited during homologous recombination to promote heteroduplex DNA extension. Mol Cell Biol 2008; 28: 1373-1382
46. Varadi V, Bevier M, Grzybowska E, Johansson R, Enquist K, Henriksson R et al. Genetic variation in genes encoding for polymerase z subunits associates with breast cancer risk, tumour characteristics and survival. Breast Cancer Res Treat 2011; 129: 235-245
47. Huertas P. DNA resection in eukaryotes: Deciding how to fix the break. Nat Struct Mol Biol 2010; 17: 11-16
48. Francis R, Richardson C. Multipotent hematopoietic cells susceptible to alternative double-strand break repair pathways that promote genome rearrangements. Genes Dev 2007; 21: 1064-1074
49. Keimling M, Volcic M, Csernok A, Wieland B, Do? rk T, Wiesmu? ller L. Functional characterization connects individual patientś mutations in Ataxia Telangiectasia Mutated (ATM) with dysfunction of specific DNA double-strand break repair signalling pathways. FASEB J 2011; 25: 3849-3860
50. Cordelli E, Cinelli S, Lascialfari A, Ranaldi R, Pacchierotti F. Melphalan-induced DNA damage in p53 and wild type mice analysed by the comet assay. Mutat Res 2004; 550: 133-143
51. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One 2011; 6: e19198
52. Tchatchou S, Riedel A, Lyer S, Schmutzhard J, Strobel-Freidekind O, Gronert-Sum S et al. Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity. Hum Mutat 2010; 31: 60-66
53. Ralhan R, Kaur J, Kreienberg R, Wiesmu? ller L. Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases. Cancer Lett 2007; 248: 1-17
54. Toyota M, Suzuki H. Epigenetic drivers of genetic alterations. Adv Genet 2010; 70: 309-323
55. Jerry DJ, Kuperwasser C, Downing SR, Pinkas J, He C, Dickinson E et al. Delayed involution of the mammary epithelium in BALB/c-p53null mice. Oncogene 1998; 17: 2305-2312
56. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-2504